Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New contrast dye could sharpen brain scans

NCT ID NCT03996447

Diagnosis Sponsor: Guerbet Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 3 trial tested a new contrast agent called gadopiclenol for MRI scans of the brain and spine. The study involved 260 people with known or suspected central nervous system lesions. The goal was to see if gadopiclenol improves the visibility of lesions compared to scans without contrast and to an existing contrast agent.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gadopiclenol
What this could lead to
If successful, this could provide a safer and more effective contrast agent for MRI scans, helping doctors see brain and spine lesions more clearly.
What could go wrong
This is a completed Phase 3 trial, but results may not show a significant advantage over existing agents. Safety concerns with gadolinium-based contrasts remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

260 people

The number who actually took part.

Started

Jun 2019

Finished

Sep 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) based on results of a previous imaging procedure such as Computed Tomography (CT) or MRI, which should have been performed within 12 months prior to ICF signature. Exclusion Criteria: * Patient presenting with acute or chronic renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent injection * Patient presenting extra cranial lesions and/or extra-dural lesions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood brain barrier defect are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood brain barrier defect CNS lesion

Contacts and locations

Locations

  • ASCLEPES Research Centers

    Panorama City, California, 91402, United States

  • ASL 1 Abruzzo Avezzano-Sulmona-L'Aquila, Ospedale Regionale San Salvatore

    L’Aquila, Italy

  • Asan Medical Center

    Seoul, 5505, South Korea

  • Axis Heilsa S. de R.L. de C.V. (Althian)

    Monterrey, 64060, Mexico

  • Azienda Sanitaria Universitaria Integrata di Trieste-PO Cattinara

    Trieste, 34149, Italy

  • CHRU - Hôpital Roger Salengro - Neurologie

    Lille, France

  • CHRU Strasbourg Hôpital de Hautepierre

    Strasbourg, 67098, France

  • CHU La Miletrie

    Poitiers, France

  • Centre Hospitalier Sainte-Anne

    Paris, 75014, France

  • Clinical Research Institute S.C

    Tlalnepantla, 54055, Mexico

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hungary

  • Fondazione I.R.C.C.S. C.Mondino

    Pavia, 27100, Italy

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital del Mar

    Barcelona, 08003, Spain

  • Istituto Neurologico Mediterraneo-Neuromed, I.R.C.C.S.

    Pozzilli, 86077, Italy

  • Konkuk University Medical Center

    Seoul, 05030, South Korea

  • M.D. Anderson Cancer Center Madrid

    Madrid, 28033, Spain

  • Northwest Neurology, Ltd.

    Rolling Meadows, Illinois, 600008, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • Orszagos Klinikai Idegtudomanyi Intezet

    Budapest, 1145, Hungary

  • Pecsi Tudomanyegyetem Klinikai Kozpont - Idegsebeszeti Klinika

    Pécs, Pécs, Hungary

  • Semmelweis Egyetem - Neurology

    Budapest, 1083, Hungary

  • South Carolina Clinical & Translational Research (SCTR) Institute

    Charleston, South Carolina, 29425, United States

  • Szegedi Tudomanyegyetem AOK

    Szeged, 6725, Hungary

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • UZ Brussel - Campus Jette

    Brussels, 1090, Belgium

  • Uniklinik Mannheim

    Mannheim, 68167, Germany

  • University Of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University Of Washington - Medical Center

    Seattle, Washington, 98195, United States

  • University of Connecticut Health Center

    Farmington, Connecticut, 06030, United States

  • University of Missouri Hospital and Clinic

    Columbia, Missouri, 65212, United States

  • Uniwersyteckie Centrum Kliniczne w Gdańsku, Zakład Radiologii

    Gdansk, 80-214, Poland

  • ZNA Middelheim

    Antwerp, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.